Overview
This is an observational data registry study of all pediatric cancer patients at Atrium Health (AH) and participating Beat Childhood Cancer Consortium sites involving specimen banking and data collection.
Description
This observational registry and banking study is being performed on a large cohort of patients who have been identified to receive molecular testing to better understand the relationship between genomic and molecular information and clinical outcomes, enabling timely and informed treatment decisions by physicians for cancer patients. We hypothesize that large gene panels, sequencing (DNA/RNA), and epigenetics of tumors can identify molecular aberrations in tumors that can be leveraged to offer more effective treatment. Findings may suggest additional research will be required to better understand the molecular underpinnings of the relationship between molecular abnormalities and disease. Banked specimens and the creation of tumor cell lines and xenograft models will enable this research to be performed.
Eligibility
Inclusion Criteria:
- No age restrictions
- Patients with suspected or confirmed pediatric tumors
- Subject or his/her legally authorized representative (where applicable) signs the study consent.
Exclusion Criteria:
- Patient or his/her legally authorized representative (where applicable) did not consent for specimen banking and data collection for this study.